Healthcare professionals education material for Talvey.

Talvey Patient Card

Patient Diary - to help you keep track of your appointments for liver function tests during the first year of treatment

This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan.

Patient Card to be carried at all times to signify treatment with Tegsedi. Card provides treatment information for the HCP, and details for patients the associated risks of treatment and when to contact the HCP for advise.

Patient card to be carried at all times. For a hardcopy Patient Card please contact Medical Information via the contact details below.

Teriflunomide – Healthcare professional (HCP) – Education / Discussion Guide - Risk Minimisation Information for Healthcare Professionals

Teriflunomide – Patient Card - Risk Minimisation Information for Patients

At first prescription, the prescriber/healthcare professional (HCP) should discuss with the patient the risks described within the discussion guide. The guide is aimed at increasing awareness about the potential risk of haematological effects and liver effects, risk of hypertension, serious infections and teratogenicity with teriflunomide and providing guidance on how to manage that risk. For hard copies of this information, please contact axunio Pharma directly via email to [email protected].

HCP guide

Patient alert card

Provides guidance to HCPs on the risks associated with teriflunomide and explains that patients should be regularly consulted about these risks. Potential risks are described as are monitoring methods. Risk of teratogenicity is described and that teriflunomide is contraindicated in pregnancy. Specific guidance on this subject is also offered.

Testosterone Educational Material

Information to healthcare professionals

Guidance on the administration of Testosterone undecanoate 1000 mg/4 ml solution for injection (testosterone undecanoate)

This pack contains the all the additional Risk Minimisation Materials required to prescribe and dispense Thalidomide BMS®. It also contains important reporting forms, information for patients, prescribing tools, and the Pharmacy Registration Form. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing Thalidomide BMS® for any patient.

A newly completed Prescription Authorisation Form must accompany each Thalidomide BMS® prescription to confirm that the patient has been counselled about the teratogenic risk of Thalidomide BMS® and the required contraceptive methods, continues to use effective contraception and in the case of a woman of childbearing potential, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant. Completion of this information is mandatory for ALL patients.

Form to report an adverse event

Event specific questionnaire for HCP

Pregnancy report form for patients on Thalidomide

Healthcare Professionals Educational Guide

Patient Card

Patient-Carer Education Brochure

Prescribing Checklist

Tolvaptan▼ Healthcare Professional (HCP) prescribing checklist for treatment initiation

Patient Alert Card

Important safety information on hepatotoxicity for patients and carers

Important information on minimising the risk of hepatotoxicity.

This non-promotional material has been developed and funded by Dr. Reddys’s Pharmaceuticals (UK) Ltd and is intended for UK HCPs treating patients with tolvaptan.

Patient card for patients being treated with Tolvaptan.

Patient/Carer Brochure

Tolvaptan Healthcare Professional (HCP) prescribing checklist for treatment initiation

Topiramate - Annual Risk Awareness Form (Epilepsy)

Topiramate - Annual Risk Awareness Form (Migraine)

Topiramate - Healthcare Professional Guide (Epilepsy)

Topiramate - Healthcare Professional Guide (Migraine)

Topiramate - Patient Card

Topiramate - Patient Guide (Epilepsy)

Topiramate - Patient Guide (Migraine)

Provides important safety information for all patients who could become pregnant.

The patient card includes important safety information for patients who could become pregnant.

Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form: Epilepsy

Topiramate should not be used in patients of childbearing potential unless the conditions of the Pregnancy Prevention Programme are fulfilled. This form outlines the condition of the topiramate Pregnancy Prevention Programme and when these must be fulfilled. This form should be used to support and record the prescribing decision

Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form - Prophylaxis of Migraine:

Topiramate should not be used in patients of childbearing potential unless the conditions of the Pregnancy Prevention Programme are fulfilled. This form outlines the conditions of the topiramate Pregnancy Prevention Programme and when these must be fulfilled. The form should be used to support and record the prescribing decision.

Topiramate Pregnancy Prevention Programme Information on the risks of topiramate use in girls (of any age) and women of childbearing potential in the treatment of epilepsy.

Topiramate Pregnancy Prevention Programme Information on the risks of topiramate use in women of childbearing potential in the treatment of prophylaxis of migraine

Important information for all female patients who could become pregnant

Topiramate Pregnancy Prevention Programme Patient Guide: What patients who are able to get pregnant need to know about topiramate

Topiramate Pregnancy Prevention Programme Patient Guide: What patients who are able to get pregnant need to know about topiramate

Sticker for Pharmacies - WARNING FOR WOMEN WHO ARE ABLE TO BECOME PREGNANT

IMPORTANT SAFETY INFORMATION GUIDE FOR HEALTHCARE PROFESSIONALS

• This document is supplied as a guide to avoid medication errors. Please refer to the Summary of

Product Characteristics before prescribing and dispensing a Toujeo® pen.

• Please provide your patients with the Patient Guide prior to prescribing or dispensing Toujeo® for

the first time or when switching to a new pen to ensure that your patients and their carers are

adequately informed on how to use Toujeo® to help reduce the risk of medication errors.

IMPORTANT SAFETY INFORMATION GUIDE FOR PATIENTS AND/OR CARERS:

• If you are prescribed Toujeo® you must be trained on how to use the Toujeo® pen by your healthcare professional and you must read the full Instructions For Use leaflet accompanying the pen.
• This document is provided as a guide.
• Start with the dose in units as prescribed by your healthcare professional

NovoPen 6 user manual

NovoPen Echo plus user manual

Important information about Truxima® (rituximab) to assist healthcare professionals (for non-oncology indications).

Patient alert card

Important safety information for patients (or for parents/legal guardians of paediatric patients).

A guide to assist healthcare professionals with the dose preparation and administration of TYENNE therapy

A patient alert card intended to educate patients and carers on the risk of PML whilst on natalizumab treatment and for up to 6 months afterwards, on the nature of PML and to ensure they exercise vigilance regarding its development.

Physician Information and Management Guidelines intended to inform physicians on the risk and the nature of PML, risk factors for development of PML, its diagnosis and treatment, specific steps to be taken to minimize this risk and the identification and management of possible sequelae (e.g. immune reconstitution inflammatory syndrome [IRIS]).

A treatment continuation form intended to educate patients and carers on the risk of PML whilst on natalizumab treatment and for up to 6 months afterwards, on the nature of PML and to ensure they exercise vigilance regarding its development.

A treatment discontinuation form intended to educate patients and carers on the risk of PML whilst on natalizumab treatment and for up to 6 months afterwards, on the nature of PML and to ensure they exercise vigilance regarding its development.

A treatment initiation form intended to educate patients and carers on the risk of PML whilst on natalizumab treatment and for up to 6 months afterwards, on the nature of PML and to ensure they exercise vigilance regarding its development.

Patient alert card regarding PML risk when using Tysabri

Physician information regarding PML risk for Tysabri

Treatment continuation form for HCPs for IV and SC presentations

Treatment discontinuation form for HCPs for IV and SC presentations

Treatment initiation form for Tysabri

Checklist for self-administration of Tysabri 150mg presentation

HCP guide for self-administration for Tysabri 150mg presentation

This guide is for healthcare professionals (HCPs) involved in the management of patients treated with Teplizumab.

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected].

Educational material for patients on important safety information associated with Teplizumab.

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected].